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most important cost drivers in COPD. The purpose of this analy-
sis was to assess the cost-effectiveness of tiotropium, a once daily
inhaled anticholinergic. METHODS: A cost-effectiveness analy-
sis has been performed, deﬁning effectiveness as each exacerba-
tion avoided. Effectiveness data of tiotropium and comparator
have been obtained from a one-year clinical trial comparing
tiotropium plus standard treatment (short-acting beta-
adrenergic and/or inhaled/oral corticoids) with placebo plus
standard treatment (deﬁned as above), which showed that the
group receiving tiotropium had less exacerbations per year (1.57
vs. 2.41; p < 0.01)1 Health care resources utilization has been
taken from the same clinical trial, a systematic review of the lit-
erature, and a local expert panel. The analysis has only included
direct medical costs from the perspective of the Spanish National
Health System. Drug costs were taken from an ofﬁcial source
and other costs from a Spanish health care cost database, both
dated 2005. The time horizon selected was one year, the follow-
up period of the aforementioned clinical trial. RESULTS: Total
costs per patient in the tiotropium group was €1388 and in the
placebo group €1119. Hospitalisation costs accounted for 44%
and 84% in the tiotropium and placebo group, respectively. The
incremental cost-effectiveness ratio was €320 to prevent one
exacerbation in a COPD patient when using tiotropium instead
of placebo. CONCLUSIONS: The use of tiotropium in addition
to the standard treatment as deﬁned in the clinical trial from
which effectiveness data were derived is a cost-effective measure
in the management of patients with COPD in Spain. 1MISTRAL
study—Eur Resp J 2004;24(Suppl. 48):S513.
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OBJECTIVE: To estimate the cost-effectiveness of Tiotropium
compared with Salmeterol in Greece from the perspective of
National Health System. METHODS: A Markov model was
structured around disease states and exacerbations based on
patient-level data derived from clinical trials comparing
tiotropium (18 ìg qd) with Salmeterol (50 ìg bid) [1]. At the start
of the model simulation, 20% of the patients were assumed to
have moderate COPD, 50% severe and 30% very severe COPD
according to the international GOLD classiﬁcation. During each
Markov cycle patients had a certain probability to experience a
severe or non-severe exacerbation. An exacerbation was clini-
cally deﬁned as a complex of respiratory symptoms. Costs of
exacerbations were divided into hospitalization and other costs.
Total costs comprise of the costs for exacerbations and mainte-
nance therapy. All costs are expressed in 2004 Euro. The time
horizon of the analysis was one year. RESULTS: The mean
number of exacerbations per patient in one year was 0.92 in the
tiotropium arm, and 1.1 in the salmeterol arm, resulting in 0.18
exacerbations avoided per patient and year when using
tiotropium instead of salmeterol. The total costs per patient in
one year were €1.324 in the tiotropium arm, and €1.239 in the
salmeterol arm, resulting in a cost difference of €85. The higher
acquisition costs for tiotropium were almost offset by savings in
hospitalisation costs. The incremental cost per exacerbation
avoided was €472. CONCLUSION: Tiotropium appears to be a
cost-effective treatment for the Greek health care system with
acceptable costs per exacerbation avoided. [1] Oostenbrink J,
Rutten-van Molken M, Monz B, FitzGerald J. Probabilistic
Markov model to assess the cost-effectiveness of bronchodilator
therapy in COPD patients in different countries. Value Health
2005;8:32–46.
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OBJECTIVES: To evaluate short term cost-effectiveness of fen-
spiride therapy in patients with chronic bronchitis exacerbations
in Poland. METHODS: A cost-effectiveness analysis was per-
formed based on the results of a randomized controlled clinical
trial comparing fenspiride and placebo in the concomitant treat-
ment of chronic bronchitis. The study population (n = 183 age
57 ± 9) was treated with fenspiride 80mg or placebo twice daily
for 6 months. The number and duration of acute exacerbations
of chronic bronchitis (AECB) deﬁned according to the American
Thoracic Society were the main efﬁcacy criteria. Cost analysis
was performed from the societal perspective. Costs of medical
consultations and diagnostic tests were based on the Polish
National Health Fund rates index. Indirect costs were calculated
using human capital approach. RESULTS: Number and duration
(days) of AECB over 6 months were lower in the fenspiride group
compared to the placebo group, on average 0.56 vs. 1.0 and 3.21
vs. 6.54, respectively. The number needed to treat (NNT) to
avoid an AECB episode was 2.27 over 6 months. In the popu-
lation of patients with exacerbations, 32% of fenspiride group
and 60.5% of placebo group experienced more than one AECB
episode. In this population the NNT to avoid an AECB episode
was 1.85 over 6 months. Taking only direct costs into consider-
ation, the incremental cost-effectiveness ratio of fenspiride was
€19.61 for one AECB episode. Indirect costs equaled €43.79 per
patient per one day of AECB. In the fenspiride group indirect
costs constituted 61% and in the placebo group 82% of the total
costs. Including direct and indirect costs, fenspiride concomitant
treatment is a cost-saving alternative. CONCLUSION: In
Poland, concomitant treatment of chronic bronchitis with fen-
spiride is a cost-effective alternative in patients who experienced
AECB.
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OBJECTIVES: To compare early polipectomy based strategy
with initial treatment with ﬂuticasone propionate nasal drops
(FPND) for the treatment of bilateral nasal polyposis in adults
in Poland. METHODS: A decision analytic model was developed
to reﬂect current clinical practice in management of bilateral
nasal polyposis in Poland. Early polypectomy, preceded by com-
puted tomography and followed by FPND for four months was
compared with initial treatment with FPND. In case of treatment
failure of the drug based strategy, patients were treated with sys-
temic corticosteroids and thereafter polypectomy. Data on treat-
ment methods efﬁcacy were derived from literature review. Cost
analysis was performed from payer perspective. Sensitivity analy-
sis focused on surgical treatment costs and FPND efﬁcacy.
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RESULTS: The strategy based on initial treatment with ﬂutica-
zone propionate nasal drops resulted with treatment cost of PLN
768, while early polypectomy resulted with cost of PLN 1251.
When surgery was performed in outpatients’ settings the mean
treatment costs were PLN 586 for initial ﬂuticazone and PLN
751 for early polypectomy. Sensitivity analysis revealed that
FPND is less costly therapy unless no computed tomography is
performed prior to polypectomy and the cost of surgical proce-
dure falls below PLN 170. CONCLUSIONS: Treatment strategy
based on ﬂuticasone propionate nasal drops is effective in bilat-
eral nasal polyposis and results in short-term cost savings.
PRS9
COST OF COMMUNITY ACQUIRED PNEUMONIA (CAP)
TREATMENT WITH KETEK (TELITHROMYCIN) VS
CLARITHROMYCIN FROM PUBLIC PAYER PERSPECTIVE 
IN POLAND
Kawalec P1, Lis J2, Gierczynski J2
1Jagiellonian University, Krakow, Poland; 2Sanoﬁ-Aventis Poland,
Warsaw, Poland
OBJECTIVES: To assess the clinical effectiveness and economic
consequences of telithromycin or clarithromycin in CAP treat-
ment from public payer perspective in Poland. METHODS:
Results of a systematic review of published clinical trials selected
in accordance with EBM criteria were used to assess effective-
ness and safety of the antibiotics in CAP treatment. The eco-
nomic consequences for public payer for therapy of individual
patient in case of clarithromycin replacement by Ketek
(telithromycin) were calculated. In this analysis it was assumed
that only pharmacotherapy costs and CAP hospitalization costs
differed; other costs were assumed to be the same irrelevant to
the antibiotic used. An assumption was made that level of phar-
macotherapy reimbursement in case of treatment with both
telithromycin and clarithromycin would be the same, public
payer costs for DDD were calculated. Costs of CAP hospitaliza-
tion varied on number of admissions during 1 month of follow-
up period. RESULTS: Clinical effects of the two drugs were
similar and no signiﬁcant differences in effectiveness or safety
were found in pooled data from two randomized clinical trials.
Telithromycin treatment was associated with signiﬁcantly fewer
CAP-related hospitalizations compared with clarithromycin
(1.6% vs 3.6% patients admitted, respectively). CAP-related
hospital costs per patient were much lower for telithromycin
treatment compared with clarithromycin (35.5pln (8.45E) vs.
79.2pln (18.8E) respectively). Taking into account reimburse-
ment of pharmacotherapy and costs of hospitalization, public
payer savings when using telithromycin in place of claritromycin
could be as high as 33pln(7.8E) - 50pln(12E)/patient (based on
sensitivity analysis). This lead to high annual savings for public
payer. CONCLUSIONS: Ketek (telithromycin) in place of clar-
ithromycin lead to signiﬁcant savings for public payer in CAP
treatment in Poland.
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OBJECTIVE: This study aimed to project future costs of asthma
and chronic obstructive pulmonary disease (COPD) in The
Netherlands for the period 2000–2025. METHODS: Gender-,
age- and (for COPD) disease-stage speciﬁc data on direct,
medical costs per patient were obtained from a cost of illness
study for the year 2000. Cost projections over the period
2000–2025 were based on two types of projections of the preva-
lence of asthma and COPD. Both prevalence projections were
combined with two types of cost projections; ﬁrst assuming con-
stant costs per patient and second adding asthma and COPD-
speciﬁc trends in costs for hospital care (asthma, -4.7% and
COPD, -4.1% per year) and medication (+4.9% per year) and
general trends in remaining cost categories. RESULTS: In 2000
the annual costs per asthma patient were €315, compared to
€915 for a COPD patient. Assuming constant costs per patient,
costs were projected to increase from €141 million in 2000 to
amounts between 167 and €181 million for asthma and from
280 to €443–495 million for COPD. Severity stage speciﬁc
COPD costs increased from 22.6 to 51.2 for mild COPD, from
104 to 148 for moderate, from 99.0 to 140 for severe and from
54.5 to €156 million for very severe COPD. Including trends
costs categories resulted in estimates between 460 and 497 for
asthma and 1023 and €1130 million for COPD. CONCLU-
SION: Projections of future costs show that the absolute and rel-
ative increase in costs over the period 2000–2025 is higher for
COPD than for asthma.
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OBJECTIVES: To assess the cost of managing COPD (health
care payers perspective) in a real life setting in Belgium.
METHODS: A multi-centre observational study with data-
collection in a retrospective way (one-year) was performed. A
total of 38GPs and 15pneumologists participated. Patients con-
sulting the physicians in Q4 2004–Q1 2005 were eligible. Indi-
vidual data-collection sheets per patient, evaluating the yearly
medical resource use, were completed by each investigator. Diag-
nostic methods, COPD severity, as well as smoking habits were
evaluated. RESULTS: A total of 460 patients were evaluated.
Mean age was 66 years, males represented 68.70%. 40.43% of
patients were smokers (average n pack-years 36.69, StErr 1.54),
50.22% ex-smokers. COPD diagnosis was made in about half
of the patients by both clinical evaluation and spirometry. A total
of 13% of the patients had mild COPD, 47% moderate, 30%
severe and 10% very severe COPD according to clinical evalua-
tion or spirometry (GOLD-guidelines). A total of 73% of the
patients experienced at least 1 exacerbation during the 1-year-
study-period. Yearly number of exacerbations ranged between 0
and 12 (average n: 1.37, median: 1.00). In most cases (69.64%),
no hospitalisation was needed. If hospitalized, average hospital
stay per exacerbation was 13.30 days (StErr 1.03). Yearly
COPD-maintenance-treatment cost ranged between 390€ (mild)
to €1117 (very severe COPD). Maintenance-treatment included
a wide range of medications. Management of COPD resulted in
a total yearly cost of €1810 (StErr 139.55, range €537 (mild
COPD)—€5888 (very severe COPD)), including maintenance-
treatment (€670, StErr 26.67), hospitalisation (€1073, StErr
130.16) and treatment of exacerbations (€67, StErr 6.78). CON-
CLUSIONS: Management of COPD is costly, mainly due to the
cost of hospitalisations. For very severe COPD patients, yearly
management costs increase up to almost €6000.
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